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MaOBJECTIVES This study aimed to explore the hemodynamic index–guided hydration method for patients with
congestive heart failure (CHF) and chronic kidney disease (CKD) to reduce the risk of contrast-induced nephropathy (CIN)
and at the same time to avoid the acute heart failure.
BACKGROUND Patients at moderate or high risk for CIN should receive sufﬁcient hydration before contrast application.
METHODS This prospective, randomized, double-blind, comparative clinical trial enrolled 264 consecutive patients with
CKD and CHF undergoing coronary procedures. These patients were randomly assigned to either central venous pressure
(CVP)-guided hydration group (n ¼ 132) or the standard hydration group (n ¼ 132). In the CVP-guided group, the
hydration infusion rate was dynamically adjusted according to CVP level every hour. CIN was deﬁned as an absolute
increase in serum creatinine (SCr) >0.5 mg/dl (44.2 mmol/l) or a relative increase >25% compared with baseline SCr.
RESULTS Baseline characteristics were well-matched between the 2 groups. The total mean volume of isotonic saline
administered in the CVP-guided hydration group was signiﬁcantly higher than the control group (1,827  497 ml vs.
1,202  247 ml; p < 0.001). CIN occurred less frequently in CVP-guided hydration group than the control group
(15.9% vs. 29.5%; p ¼ 0.006). The incidences of acute heart failure during the hydration did not differ between the
2 groups (3.8% vs. 3.0%; p ¼ 0.500).
CONCLUSIONS CVP-guided ﬂuid administration can safely and effectively reduce the risk of CIN in patients with
CKD and CHF. (Central Venous Pressure Guided Hydration Prevention for Contrast-Induced Nephropathy; NCT02405377)
(J Am Coll Cardiol Intv 2016;9:89–96) © 2016 by the American College of Cardiology Foundation.I ncidence of contrast-induced nephropathy (CIN)is reported to be more than 20% in chronic kid-ney disease (CKD) complicated with congestive
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ABBR EV I A T I ON S
AND ACRONYMS
CHF = congestive heart failure
CIN = contrast-induced
nephropathy
CKD = chronic kidney disease
CVP = central venous pressure
eGFR = estimated glomerular
ﬁltration rate
LVEF = left ventricular ejection
fraction
SCr = serum creatinine
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90is the cornerstone for prevention of CIN,
because hydration could increase the renal
ﬂow, reducing the contraction of renal ves-
sels and the formation of urinary casts (7–9).
The guidelines recommend controlling the
hydration rate in patients with CHF to avoid
acute pulmonary edema. However, inade-
quate hydration markedly increases the inci-
dence of CIN in patients with CKD (9). We
expect to explore an individual hydration
method for CKD-complicated CHF patients
to reduce the incidence of CIN and, at the
same time, to prevent acute heart failure.METHODS
The study was a prospective, randomized, double-
blind clinical trial, conducted in China from February
2014 to February 2015. This trial was registered with
ClinicalTrials.gov (NCT02405377). The study was ap-
proved by the institutional review board of the Chinese
People’s Liberation Army General Hospital and per-
formed in conformity with the Helsinki Declaration
of 1975, as revised in 2000. The ethical committee of
our institution approved the protocol. Written
informed consent was provided by all patients before
enrollment.SEE PAGE 97STUDY POPULATION. We enrolled patients from
February 2014 to December 2014. The principal in-
clusion criteria included: 1) CHF: left ventricular
ejection fraction (LVEF) by echocardiography <50%
and with a typical attack of congestive left heart
failure in the past 1 year, which presented with
paroxysmal nocturnal dyspnea or orthopnea with
obvious rales or wheezes in lungs; 2) CKD: estimated
glomerular ﬁltration rate (eGFR) from 15 to 60
ml/min/ 1.73 m2, calculated via the Modiﬁcation of
Diet in Renal Disease study equation (10); and 3) pa-
tients scheduled to undergo diagnostic cardiac angi-
ography or percutaneous coronary intervention.
The principal exclusion criteria included: dialysis-
dependent patients; age <18 years; pregnancy;
lactation; emergency cardiac catheterization (e.g.,
primary percutaneous coronary intervention for ST-
segment elevation myocardial infarction); exposure
to radiographic contrast media within the previous
7 days; acute decompensated heart failure; and
cardiogenic shock. We randomly assigned eligible
patients at a 1:1 ratio to either central venous pressure
(CVP)-guided hydration or standard hydration pro-
tocol. Eligible patients were assigned with sealed
blinded envelopes that contained a computer-generated randomization number. Patients were not
told to which group they were randomly allocated.
The cardiologists performing the angiogram also had
no knowledge of each patient’s group assignment.
PROCEDURES. We used 0.9% sodium chloride hy-
dration in all patients. We monitored the CVP level by
placing a 5-F catheter in the jugular vein and recorded
initial CVP level in both groups. Patients in the
CVP-guided hydration group were divided into
3 subgroups according to initial CVP level, group 1
(CVP <6 cm H2O), group 2 (CVP 6 to 12 cm H2O), and
group 3 (CVP >12 cm H2O). The rate of ﬂuid admin-
istration was guided by CVP as follows: 3 ml/kg/h for
group 1, 1.5 ml/kg/h for group 2, and 1 ml/kg/h for
group 3. The intravenous infusion rate was dynami-
cally adjusted according to the level of CVP per hour
during hydration. If the CVP of patients experienced a
rise among the groups, (for example, if CVP increased
from 8 cm H2O to 13 cm H2O, the patient would
change from group 2 to group 3), this would necessi-
tate a reduction in the intravenous infusion rate from
1.5 ml/kg/h to 1 ml/kg/h. If the patient’s CVP
increased from 8 cm H2O to 12 cm H2O, the ﬂuid rate
remained 1.5 ml/kg/h. The control group was hy-
drated at the rate of 1 ml/kg/h. Hydration continued
from 6 h before the procedure to 12 h post-procedure,
thus both study groups received intravenous ﬂuids
for the same duration but at different rates. All study
participants received iodixanol (320 mg I/ml; Visipa-
que, GE Healthcare, Chalfont St. Giles, United
Kingdom) as the contrast medium.
ENDPOINTS AND DEFINITION. The primary endpoint
of the study was CIN, deﬁned as the peak increase in
serum creatinine (SCr) concentration either $25%
or $0.5 mg/dl (44.2 mmol/l) over baseline during the
ﬁrst 72 h post-procedure, and we further analyzed the
proportion of patients with a peak SCr increase $50%
or $1.0 mg/dl (88.4 mmol/l) over baseline in the initial
72 h post-procedure. Urine output, SCr, blood urea
nitrogen, and serum electrolytes were also evaluated
at baseline, the day of coronary angiography and
each day for the following 3 days and at hospital
discharge for assessment of acute kidney injury
severity and indication of dialysis. Secondary end-
points were major post-procedure adverse clinical
events including acute pulmonary edema, myocardial
infarction, all-cause death, and CIN requiring renal
replacement therapy. Myocardial infarction was
deﬁned as a creatine kinase-myocardial band enzyme
elevation 3 times the upper normal value with or
without new Q waves on the electrocardiogram. The
risk score of CIN was assessed on the basis of the pa-
tients’ clinical and laboratory conditions (1,3). Each
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91patient was contacted every week after administration
of the contrast medium, investigated as to whether
dialysis or main cardiovascular events had occurred
within 3 months after the coronary procedure, and any
adverse events were recorded. All adverse clinical
events, as well as study endpoints, were judged by the
independent event committee, whose members were
masked to treatment assignment.
STATISTICAL ANALYSIS. Clinical characteristics and
laboratory features of our study population were
analyzed. Data were expressed as mean  SD for
continuous variables and as percentages for discrete
variables. Continuous variables were compared be-
tween the groups using the Student t test (for normal
distribution) or Mann-Whitney rank sum test (for
nonnormal distribution). Categorical variables are
presented as numbers and percentages and were
compared with chi-square or Fisher exact tests whenFIGURE 1 Flow Diagram of the Trial
From 354 eligible patients, 269 were randomized to receive CVP-guided h
followed up and completed the study. CVP ¼ central venous pressure.there were <5 values in a given cell. We compared the
occurrence of major adverse events with the Kaplan-
Meier method using the log-rank test. All statistical
tests used a 2-sided test, and p < 0.05 indicated sta-
tistical signiﬁcance. All statistical analyses were per-
formed using SPSS statistical software (version 18.0,
SPSS, Chicago, Illinois).
We calculated the necessary sample size before
carrying on the research. According to authoritative
literature, the incidence of CIN in patients who meet
inclusion criteria is about 25% (1,3). Our preliminary
experiment showed that CVP-guided hydration could
reduce the incidence of CIN at least by 40%. On the
basis of these assumptions, chi-square analysis sug-
gested that 210 patients would be needed to detect a
statistically signiﬁcant difference, with 80% power
and a 2-sided a of 0.05. If the loss to follow-up was
10%, 120 patients were needed for each group.ydration (n ¼ 134) or standard hydration (n ¼ 135), 264 patients were
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92RESULTS
BASELINE CHARACTERISTICS AND PROCEDURES.
Of 354 consecutive eligible patients, 269 were
enrolled and randomly allocated to the CVP-guided
treatment group (n ¼ 134) or the control group
(n ¼ 135). Of these, 2 patients in the CVP-guided
treatment group and 3 patients in the control groupBasic Characteristics of Study Patients
CVP-Guided
Hydration Group
(n ¼ 132)
Control
Group
(n ¼ 132) p Value
64  10 63  12 0.524
female 101/31 96/36 0.572
73  12 70  13 0.069
167  7 166  7 0.130
2O 10  4 9  4 0.185
n of CVP 0.780
cm H2O 28 (21.2) 24 (18.2)
2 cm H2O 69 (52.3) 74 (56.1)
cm H2O 35 (26.5) 34 (25.8)
oﬁle
oronary syndrome 107 (81.1) 108 (81.8) 1.000
olesterolemia 25 (18.9) 25 (18.9) 1.000
nsion 112 (84.8) 103 (78.0) 0.267
s mellitus 67 (50.8) 58 (43.9) 0.325
of smoking 67 (50.8) 61 (46.2) 0.538
Hg 136  19 133  25 0.168
m Hg 76  13 74  14 0.366
0 mm Hg 15 (11.4) 16 (12.1) 0.500
te, beats/min 77  11 79  13 0.237
te >100 beats/min 13 (9.8) 16 (12.1) 0.347
y data
mol/l 2.48  0.87 2.39  0.95 0.432
ol/l 4.07  1.17 4.14  1.09 0.621
l 22  18 27  20 0.018
lucose, mmol/l 7.8  5.0 8.5  4.0 0.223
obin, g/l 117  24 122  24 0.096
f white blood cell, 109/l 7.72  2.89 8.36  3.67 0.118
fraction, % 40  8 39  8 0.160
ed GFR, ml/min/1.73 m2 36 (23–48) 39 (26–52) 0.224
reatinine, mmol/l 155 (130–271) 147 (113–256) 0.147
CIN risk score 13  4 13  4 0.429
risk of CIN, % 24  7 25  8 0.543
n
uretics 65 (49.2) 70 (53.0) 0.622
132 (100) 132 (100) 1.000
lcysteine 113 (85.6) 109 (82.6) 0.614
RBs 83 (62.9) 71 (53.8) 0.170
113 (85.6) 119 (90.2) 0.346
volume, ml 1,827  497 1,202  247 <0.001
edium volume, ml 161  67 171  67 0.205
ean  SD or n (%), or median (interquartile range), except for estimated GFR and
inine: median (interquartile range).
¼ angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; ALT¼ alanine
erase; CIN ¼ contrast-induced nephropathy; CVP ¼ central venous pressure; DBP ¼ dia-
pressure; GFR ¼ glomerular ﬁltration rate; LDL-c ¼ low-density lipoprotein cholesterol;
taneous coronary intervention; SBP ¼ systolic blood pressure; TC¼ total cholesterol.were excluded due to failure of jugular vein cathe-
terization, and 264 patients who were randomly
assigned to either the CVP-guided treatment group
(n ¼ 132) or the control group (n ¼ 132) completed the
study and were included in the primary analysis
(Figure 1). We followed up study patients from
February 2014 to February 2015. Baseline character-
istics and procedures for study population are shown
in Table 1. The mean age of the cohort was 64 years,
with 25% women and 47% patients with diabetes.
Baseline characteristics were well matched between
the 2 groups. The mean eGFR (median [interquartile
range]) was similar between the 2 groups (36 [23 to
48] ml/min/1.73 m2 vs. 39 [26 to 52] ml/min/1.73 m2;
p ¼ 0.224). Predicted risk of CIN (24  7% vs. 25  8%,
p ¼ 0.543) were comparable between the 2 groups.
The distributions of CVP were well matched between
the 2 groups (p ¼ 0.780). The total mean volume of
saline administered in the CVP-guided group was
signiﬁcantly higher than in the control group (1,827 
497 ml vs. 1,202  247 ml; p < 0.001) (Figure 2);
meanwhile, patients in the CVP-guided hydration
group had a higher volume of urine output than the
control group (1,461  453 ml vs. 806  228 ml; p <
0.001). In a different phase of hydration, the volumes
of isotonic saline administered in the CVP-guided
hydration group were all signiﬁcantly higher than in
the control group (719  331 ml vs. 385  71 ml in the
pre-procedural phase, p < 0.001; 130  66 ml vs. 86 
45 ml in intraprocedural phase, p ¼ 0.004; 978 
403 ml vs. 731  181 ml in post-procedural phase,
p < 0.001).FIGURE 2 Hydration Volumes of Normal Saline Administered
in Each Group
The box for each group represents the 25th percentile to the
75th percentile of the data. The whiskers start from minimum
data point to the maximum data point. The mean of hydration
volumes was signiﬁcantly higher in the CVP-guided hydration
group than in the control group. CVP ¼ central venous pressure.
FIGURE 3 Relationship Between Absolute SCr Change and
Total Hydration Volume
The dotted line indicates the 0.5 mg/dl of serum creatinine (SCr)
increase from baseline used for the deﬁnition of contrast-induced
nephropathy. There is a strong negative correlation between
hydration volume and increase of SCr.
TABLE 2 Incidence of CIN in Study Patients
Deﬁnition
of CIN
CVP-Guided
Hydration Group
(n ¼ 132)
Control Group
(n ¼ 132)
Absolute Difference
(95% CI) p Value
SCr >50% [ 5 (3.79) 13 (9.85) 3.1 (0.0–12.1) 0.042
SCr >25% [ 19 (14.4) 32 (24.2) 9.8 (0.3–19.4) 0.030
SCr >0.5 mg/dl [ 18 (13.6) 35 (26.5) 4.9 (3.3–22.5) 0.007
SCr >0.3 mg/dl [ 26 (19.7) 46 (34.8) 15.2 (4.5–25.8) 0.004
Incidence of CIN 21 (15.9) 39 (29.5) 13.6 (3.6–23.7) 0.006
Values are n (%).
CI ¼ conﬁdence Interval; SCr ¼ serum creatinine; other abbreviations as in Table 1.
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93INCIDENCE OF CIN. The overall incidence of CIN for
enrolled high-risk patients was 22.7% (60 of 264): it
was 15.9% (21 of 132) in the CVP-guided hydration
group versus 29.5% (39 of 132) in the control group
(p ¼ 0.006). The absolute risk difference was 13.6%
(95% conﬁdence interval: 3.6% to 23.7%). The pro-
portion of patients with SCr increasing >0.3 mg/dl
and >50% from baseline were both signiﬁcantly lower
in the CVP-guided hydration group than in the control
group (3.79% vs. 9.85%; p ¼ 0.042 in SCr >50%; 19.7%
vs. 34.8%; p ¼ 0.004 in SCr >0.3 mg/dl) (Table 2).
Differences of outcomes in CIN between study groups
were probably due to more aggressive volume
expansion guided by CVP. The whole study cohort
was divided into 3 groups on the basis of the volume
of isotonic saline received. The volume of ﬂuid in
each group was: group 1 (500 to 1,000 ml), group 2
(1,000 to 1,500 ml), and group 3 (>1,500 ml). The
corresponding rates of CIN were 37.9% (11 of 29) for
group 1, 31.3% (41 of 131) for group 2, and 7.7% (8 of
104) for group 3. There was a strong negative cor-
relation between hydration volume and the increase
of SCr (r ¼ 0.21, p < 0.001) (Figure 3). We analyzed
the relationship between CIN and subgroups
deﬁned by level of LVEF and CVP. The patients
with worse LVEF (<40%) got more beneﬁt for CIN
prevention from the hydration guided by CVP
dynamic monitoring (17.5% vs. 33.3%; p ¼ 0.031),
and the patients with the lowest CVP level (<6 cm
H2O) received the greatest beneﬁts from the CVP-
guided hydration (10.7% vs. 37.5%; p ¼ 0.045), as
shown in Table 3.
ADVERSE EVENTS. During the hospital stay and out
to 90 days after the procedure, myocardial infarction
incidence was much lower in the CVP-guided treat-
ment group than in the control group (4 [3.0%] vs. 13
[9.8%]; p ¼ 0.019], and renal replacement therapy
was also signiﬁcantly lower in the CVP-guided treat-
ment group than in the control group (4 [3.0%] vs.
13 [9.8%]; p ¼ 0.019). Although the volume of the
isotonic saline received was much higher in the CVP-
guided group than the control group, the aggressive
volume expansion was terminated at a similarly low
rate because of acute pulmonary edema (5 [3.8%] vs.
4 [3.0%]; p ¼ 0.500), and 52 patients in the CVP-
guided hydration group had a reduction in the infu-
sion rate due to an obvious increase of CVP. The
incidence of 90-day acute heart failure did not
differ between the 2 groups (9 [6.8%] vs. 10 [7.6%];
p ¼ 0.500). Nine patients who had an episode of acute
pulmonary edema during hospitalization had worse
LVEF (35  6% vs. 40  8%; p ¼ 0.061), higher initial
CVP level (15  1 cm H2O vs. 9  4 cm H2O; p < 0.001),higher heart rate (94  20 vs. 78  12; p < 0.001),
lower eGFR (24  13 ml/min/1.73 m2 vs. 40  21
ml/min/1.73 m2; p ¼ 0.019), and received a
higher volume of contrast medium (217  75 ml vs.
164  66 ml; p ¼ 0.019) compared with other study
patients who did not experience acute pulmonary
edema, and they received a lower hydration volume
compared with other study patients (1,220  250 ml
vs. 1,525  505 ml; p ¼ 0.073); however, a lower hy-
dration volume still did not prevent acute pulmonary
edema. Ninety days after the procedure, cumulative
major adverse events were reported in 8.3% (11 of 132)
of patients in the CVP-guided hydration group
compared with 20.5% (27 of 132) in the control group
(p ¼ 0.004) (Table 4). Figure 4 shows the occurrence
of major adverse events during the 90-day follow-up
by treatment group (p for log-rank ¼ 0.005). We also
reported the rate of major adverse events by CIN. In
TABLE 4 Ninety-Day
All-cause mortality
Myocardial infarction
Renal replacement the
Cumulative major adve
Values are n (%).
Abbreviations as in Tabl
FIGURE 4 Cumulative Major Adverse Events at 90 Days for
the CVP-Guided Hydration Group Versus Control Group
The graph shows the 3-month major adverse events, deﬁned as a
composite of all-cause mortality, myocardial infarction, and
acute renal failure requiring dialysis in each group. CVP ¼ central
venous pressure.
TABLE 3 Incidence of CIN in Study Patients by Subgroups
CVP-Guided
Hydration Group
Control
Group
Absolute Difference,
% (95% CI) p Value
LVEF
40%–50% 10/69 (14.5) 17/66 (25.8) 11.3 (2.3 to 24.8) 0.077
<40% 11/63 (17.5) 22/66 (33.3) 15.8 (0.9 to 30.9) 0.031
CVP
<6 cm H2O 3/28 (10.7) 9/24 (37.5) 26.8 (4.0 to 49.6) 0.045
6–12 cm H2O 8/69 (11.6) 20/74 (27.0) 15.4 (2.5 to 28.4) 0.022
>12 cm H2O 10/35 (28.5) 10/34 (29.4) 0.8 (21.3 to 23.0) 0.939
Values are n/N (%).
LVEF ¼ left ventricular ejection fraction; other abbreviations as in Tables 1 and 2.
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94patients with CIN, the rate of major adverse events
was 38% (23 of 60), and patients who developed CIN
had a higher rate of all-cause mortality than those
who did not develop CIN (p ¼ 0.017).
DISCUSSION
The study population was at a high risk of CIN, and
the incidence of contrast-induced acute kidney injury
in the control group was similar to the expected
incidence according to the CIN risk score (1,3). This
trial found that CVP-guided hydration resulted in a
signiﬁcant reduction of 46% in the primary endpoint
of CIN and a signiﬁcant reduction of 59% in major
adverse clinical events compared with standard
treatment. Our study revealed that CIN could be
further reduced with CVP-guided hydration.
The mechanisms of these favorable treatment
effects are probably multifactorial. Volume ex-
pansion with saline reduced CIN by reducing the
contrast medium concentration, suppression of the
renin-angiotensin-aldosterone system, and down-
regulation of tubuloglomerular feedback, by dilution
of the contrast medium within the tubular lumen
(11–14). We found that the CVP in some of the CHF
patients were at relatively low levels, and CHF pa-
tients were often accompanied by renal perfusion
defects (15); sufﬁcient hydration could maintain aMain Adverse Events in Study Patients
CVP-Guided
Hydration Group
(n ¼ 132)
Control
Group
(n ¼ 132)
Absolute
Difference, %
(95% CI) p Value
3 (2.3) 5 (3.8) 1.5 (2.7 to 5.7) 0.722
4 (3.0) 13 (9.8) 6.8 (0.9 to 12.7) 0.019
rapy 4 (3.0) 13 (9.8) 6.8 (0.9 to 12.7) 0.019
rse events 11 (8.3) 27 (20.5) 12.1 (3.7 to 20.5) 0.004
es 1 and 2.constant intravascular volume and improve the renal
perfusion for prevention CIN (16). In patients with
CKD, hydration is usually performed at a low rate
because of the fear of overhydration and pulmonary
edema, particularly in patients with impaired left
ventricular function. It should be emphasized that
individual and adequate hydration could prevent CIN
(17–19). A new concept is emerging for CIN preven-
tion: hydration volume should be commensurate to
the risk of CIN. In support of this idea, we noted that
CVP-guided aggressive ﬂuid administration increased
urine ﬂow rates by maintenance of constant intra-
vascular volume and further reduced the risk of CIN.
As noted in current guidelines, no clear evidence
exists to guide the choice of the optimal rate of ﬂuid
administration. We sought to develop a practical and
feasible hydration protocol that can beneﬁt high CIN
risk patients. There have been some clinical trials on
optimal ﬂuid administration for CIN prevention
(17,20–23). The MYTHOS (Induced Diuresis With
Matched Hydration Compared to Standard Hydration
for Contrast Induced Nephropathy Prevention) trial
has revealed that diuresis with matched hydration
could reduce the incidence of CIN and is associated
with improved in-hospital outcome (20). RenalGuard
System-guided hydration signiﬁcantly decreased the
incidence of CIN in high-risk patients for CIN (21). The
POSEIDON (Prevention of Contrast Renal Injury With
Different Hydration Strategies) trial also showed left
ventricular end-diastolic pressure–guided hydra-
tion was safe and effective in preventing CIN and
PERSPECTIVES
WHAT IS KNOWN? Despite general agreement on hydration
being the cornerstone for prevention of CIN and strong recom-
mendation of all guidelines, CHF patients are not receiving
sufﬁcient hydration in clinical practice because of fear of
increased cardiac pre-load and pulmonary edema during hydra-
tion. CVP could objectively reﬂect change of intravascular vol-
ume status and the body’s tolerance to aggressive hydration. It is
unclear whether CVP-guided ﬂuid administration could decrease
the risk of CIN for patients with CHF and CKD.
WHAT IS NEW? This study shows aggressive volume expansion
guided by CVP (monitoring during hydration to adjust the rate
of saline administration dynamically) resulted in a signiﬁcant
46% reduction in the primary endpoint of CIN compared with
standard treatment; meanwhile, acute pulmonary edema during
hydration did not differ between the CVP-guided hydration
group and the control group. CVP-guided vigorous ﬂuid admin-
istration could avoid ﬂuid overload and effectively reduce the
risk of CIN in patients with CKD and CHF.
WHAT IS NEXT? It is still not clear that a strategy of hemo-
dynamic index–guided hydration is suitable for those patients
undergoing urgent angiography. In addition, further clinical trials
are required to determine the optimal hydration dose for CHF
patients.
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95improving the outcome (17). In our study, we applied
hemodynamic CVP instead of left ventricular end-
diastolic pressure to assess volume status and the
ability to tolerate high rates of ﬂuid administration
for these CHF patients and had made similar
conclusions.
It cannot be ignored that the hydration process also
could further increase cardiac pre-load (9,15). CVP
provides a safe and accurate assessment of intravas-
cular volume status. We adjusted the velocity of
hydration to ensure sufﬁcient hydration without
obvious increasing the volume load, and the aggres-
sive volume expansion was terminated at a similarly
low rate due to pulmonary edema (5 [3.8%] vs. 4
[3.0%]; p ¼ 0.500); 52 patients in CVP-guided hydra-
tion group had reduction in infusion rate due to an
obvious increase of CVP, all of which prove the safety
of the CVP-guided hydration procedure.
STUDY LIMITATIONS. First, this trial was a single-
center study. Second, the physicians undertaking
the hydration procedure were not blinded to the
treatment groups, which might have inﬂuenced our
results. Last, the strategy of aggressive volume
expansion was not suitable for all high-risk patients,
especially those with acute decompensated heart
failure. The conclusion needs to be tested in more
patients in multiple centers.
CONCLUSIONS
CVP-guided ﬂuid administration can safely and
effectively reduce the risk of CIN in patients with CKD
and CHF and substantially reduce composite major
adverse events for these high-risk patients.REPRINT REQUESTS AND CORRESPONDENCE: Dr.
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